



**MYDECINE**  
MEDICINE EVOLVED

## **Mydecine Innovations Group Announces Issuance of Shares for Services**

DENVER – March 22, 2021 — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: ONFA) (“Mydecine” or the “Company”) announces the issuance of 206,184 common shares of the Company (the “Shares”) effective March 11, 2021, at a deemed price of approximately \$0.336 per Share for total consideration of \$69,212.50, to a service provider as payment for consulting services provided to the Company. The Company entered into a consulting agreement with the service provider on August 31, 2020 in respect of the provision of corporate governance consulting services.

The Company has also issued, effective March 17, 2021, 83,526 Shares to Jim Gunning, chief marketing officer (“CMO”) of the Company pursuant to Mr. Gunning’s employment agreement for the services of Mr. Gunning as CMO of Mydecine for the period from September 17, 2020 to February 28, 2021. The Shares were issued at a deemed price of approximately \$0.329 each. The total compensation for the period is \$27,500. The share issuance to Mr. Gunning constitutes a "related-party transaction" within the meaning of Multilateral Instrument 61-101 ("MI 61-101") and Mydecine intends to rely on certain exemptions contained in sections 5.5(b) and 5.7(a) of MI 61-101.

### **About Mydecine Innovations Group**

Mydecine Innovations Group™ (CSE: MYCO) (OTC:MYCOF) (FSE:ONFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

Learn more at: <https://www.mydecine.com/> and follow us on [Facebook](#), [Twitter](#), and [Instagram](#).

### **Mydecine Innovations Group Media Contacts**

Anne Donohoe / Nick Opich  
KCSA Strategic Communications

adonohoe@kcsa.com / nopich@kcsa.com  
212-896-1265 / 212-896-1206

**On behalf of the Board of Directors:**

Joshua Bartch, Chief Executive Officer  
contact@mydecineinc.com

**Corp Communications:**

Charles Lee, Investor Relations  
corp@mydecineinc.com  
+1 720-277-9879

**For further information about Mydecine Innovations Group, Inc., please visit the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com) or visit the Company's website at [www.mydecine.com](http://www.mydecine.com).**

**The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.** This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management's current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.

This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

###